Latest news

Filters
August 15, 2012

Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932 – Study to test Debio…

Read more
July 24, 2012

Debiopharm Group™ – First patient treated in Phase III study with subcutaneous administration of Debio 8206 for treatment of advanced…

Read more
July 5, 2012

Debiopharm Group is investing in Tweasy, the Saas e-marketing platform for SMEs

Read more
June 20, 2012

Debiopharm Group supports venture kick

Read more
June 19, 2012

Debiopharm, Immunexpress and Biocartis Announce Collaboration to Advance Development of SeptiCyte® Triage for Managing Sepsis

Read more
June 18, 2012

Debiopharm and Ascepion Pharmaceuticals, Inc. announce an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor,…

Read more
June 6, 2012

Debiopharm Presented Results at the ASCO 2012 Annual meeting – Results of Phase I study with Debio 0932, an oral…

Read more
May 15, 2012

Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…

Read more
May 15, 2012

Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…

Read more